Alzheimer's disease (AD) is a neurodegenerative disease that is coupled with chronic cognitive dysfunction. AD cases are mostly late onset, and genetic risk factors like the Apolipoprotein E () play a key role in this process. 2, 3, and 4 are three key alleles in the human gene. For late onset, 4 has the most potent risk factor while 2 plays a defensive role. Several studies suggests that 4 causes AD via different processes like neurofibrillary tangle formation by amyloid-β accumulation, exacerbated neuroinflammation, cerebrovascular disease, and synaptic loss. But the pathway is still unclear that which actions of 4 lead to AD development. Since was found to contribute to many AD pathways, targeting 4 can lead to a hopeful plan of action in development of new drugs to target AD. In this review, we focus on recent studies and perspectives, focusing on 4 as a key molecule in therapeutic strategies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764632PMC
http://dx.doi.org/10.3233/ADR-210027DOI Listing

Publication Analysis

Top Keywords

alzheimer's disease
8
late onset
8
perspectives role
4
role therapeutic
4
therapeutic target
4
target alzheimer's
4
disease
4
disease alzheimer's
4
disease neurodegenerative
4
neurodegenerative disease
4

Similar Publications

Senescent brain cell types in Alzheimer's disease: Pathological mechanisms and therapeutic opportunities.

Neurotherapeutics

January 2025

Department of Neurology, Washington University School of Medicine in St Louis, MO, USA; St Louis VA Medical Center, St Louis, MO, USA. Electronic address:

Cellular senescence is a cell state triggered by programmed physiological processes or cellular stress responses. Stress-induced senescent cells often acquire pathogenic traits, including a toxic secretome and resistance to apoptosis. When pathogenic senescent cells form faster than they are cleared by the immune system, they accumulate in tissues throughout the body and contribute to age-related diseases, including neurodegeneration.

View Article and Find Full Text PDF

Mild cognitive impairment is a diagnostic category marked by declines in memory and cognitive function that are less severe than those observed in Alzheimer's disease. Previous studies have indicated that individuals with mild cognitive impairment have an elevated risk of progressing to Alzheimer's disease. The hippocampus is well known to play pivotal roles in memory and cognitive functions.

View Article and Find Full Text PDF

Introduction: Identifying early risks of developing Alzheimer's disease (AD) is a major challenge as the number of patients with AD steadily increases and requires innovative solutions. Current molecular diagnostic modalities, such as cerebrospinal fluid (CSF) testing and positron emission tomography (PET) imaging, exhibit limitations in their applicability for large-scale screening. In recent years, there has been a marked shift toward the development of blood plasma-based diagnostic tests, which offer a more accessible and clinically viable alternative for widespread use.

View Article and Find Full Text PDF

Searching for new drugs to treat Alzheimer's disease dementia through multiple pathways.

World J Clin Cases

January 2025

Department of Neurology, Guizhou Medical University, Guiyang 550004, Guizhou Province, China.

Dementia is a group of diseases, including Alzheimer's disease (AD), vascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson's disease dementia, metabolic dementia and toxic dementia. The treatment of dementia mainly includes symptomatic treatment by controlling the primary disease and accompanying symptoms, nutritional support therapy for repairing nerve cells, psychological auxiliary treatment, and treatment that improves cognitive function through drugs. Among them, drug therapy to improve cognitive function is important.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!